Printed From BioPortfolio.com

Promising data for Sanofi, Regeneron’s dupilumab

05:56 EDT 17 Oct 2017 | PharmaTimes

Sanofi and Regeneron have unveiled positive results from a mid-stage study exploring the potential of the biologic dupilumab in adults with eosinophilic esophagitis, and also signed a deal with Aimmune Therapeutics to test an experimental peanut allergy therapy.

Original Article: Promising data for Sanofi, Regeneron’s dupilumab

More From BioPortfolio on "Promising data for Sanofi, Regeneron’s dupilumab"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches